NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that it completed its acquisition of full-service commercial laboratory firm Solstas Lab Partners Group and its subsidiaries for $570 million. In connection with the deal, Quest raised its guidance for full-year 2014. Revenues are now expected to grow between 2 percent and 4 percent, compared to full-year 2013. It previously said 2014 revenue was anticipated to be flat to down 2 percent year over year, excluding the Solstas purchase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.